ExpertiseUpdated on 4 April 2025
Oligodendrocyte biology and remyelination platform
business developer BIOMED at Hasselt University - Biomedical Research Institute
Diepenbeek, Belgium
About
Are you developing new therapies for neurodegenerative disease that target oligodendrocyte biology or de- and remyelination?
▶ Progress your development programs faster by building on our expertise glial cell biology, neuroscience, and lipid metabolism.
▶ Our validated models are continuously exploited in proprietary research programs and service activities for the private sector.
▶ We are keen on creating collaborative and longlasting partnerships by meeting rapidly changing needs and requirements in a flexible way and delivering on our promises.
POSSIBLE APPLICATIONS
• Test the therapeutic activity of candidate therapies on oligodendrocyte biology and remyelination in vitro at three levels: differentiation and proliferation of oligodendrocyte precursor cells (OPCs), migration behaviour of OPCs and axon-wrapping potential. Multiple conditions can be tested in parallel.
• Test the effect of therapies in a more complex multicellular brain environment using ex vivo in brain slice cultures. Multiple conditions can be tested in parallel.
• Test your candidate therapies in in vivo models which includes a battery of functional, structural, and clinical outcome measures.
Attached files
Similar opportunities
Expertise
Blood-Brain Barrier in vitro to in vivo models
An Voets
business developer BIOMED at Hasselt University - Biomedical Research Institute
Diepenbeek, Belgium
Service
An Voets
business developer BIOMED at Hasselt University - Biomedical Research Institute
Diepenbeek, Belgium
Expertise
Angiogenesis in vitro to in vivo toolbox
An Voets
business developer BIOMED at Hasselt University - Biomedical Research Institute
Diepenbeek, Belgium